Under the agreement, Empyrean has an exclusive license to develop and commercialize MD Anderson researchers’ new approach for delivering radiation therapy, according to an Aug. 10 news release from the cancer center. MD Anderson will receive equity interest, royalties and other financial considerations.
The Magnetically Optimized Very High Energy Electron Therapy technology, which Empyrean will commercialize, can significantly improve the precision of radiation delivery without increasing the footprint, according to the release.
Empyrean and MD Anderson Cancer Center also intend to collaborate on new technology based on Empyrean’s intellectual property.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
